Avadel Pharmaceuticals plc (NasdaqGM: AVDL)
Health Care · Pharmaceuticals · IE
$—
— today · — 1Y
Avadel Pharmaceuticals plc (NasdaqGM: AVDL) operates in the Pharmaceuticals industry within the Health Care sector.
trading between 13.83 and 23.57.
Tweenvest scores Avadel Pharmaceuticals plc across four factors: quality 47/100, value 35/100. Its strongest factor is quality.
AVDL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $279.14M
- P/E
- —
- EPS
- 0.64
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $23.57
- 52-week low
- $13.83
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 188
- Next earnings
- —
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy. Established in 2015, the entity was formerly recognized as Flamel Technologies SA before rebranding as Avadel Pharmaceuticals plc in January 2017. Its global headquarters are situated in Dublin, Ireland.
- ISIN
- IE00BDGMC594
- Founded
- 2015
- Listed since
- Jun 7, 1996
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.06T | $1,189.41 | -3.59% |
| Johnson & JohnsonNYSE: JNJ | $650.67B | $270.00 | -1.15% |
| Merck & Co., Inc.NYSE: MRK | $377.72B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $365.10B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $300.07B | CHF127.18 | -0.90% |
| AstraZeneca PLCLSE: AZN | $257.89B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $210.23B | Dkr304.95 | -0.93% |
| Pfizer Inc.NYSE: PFE | $161.30B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.